Comparative Pharmacology
Head-to-head clinical analysis: DYSPORT versus JEUVEAU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYSPORT versus JEUVEAU.
DYSPORT vs JEUVEAU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion, thereby causing temporary muscle paralysis.
Follicle-stimulating hormone (FSH) receptor agonist; stimulates ovarian follicular development.
For cervical dystonia: 500 Units intramuscularly divided among affected muscles, repeat no sooner than every 12 weeks. For glabellar lines: 50 Units intramuscularly divided into 5 injection sites, repeat no sooner than every 3 months. For blepharospasm: 1.25-2.5 Units per injection site, total dose not to exceed 100 Units per eye per 3 months.
Intravenous infusion of 150 mg over 1 hour every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours for the complex; however, clinical duration is longer due to prolonged pharmacodynamic effects. The half-life has limited clinical relevance as recovery from neuromuscular blockade depends on neural sprouting and receptor turnover.
Terminal elimination half-life of approximately 12–15 hours in healthy adults; may be prolonged in renal impairment.
Primarily eliminated via hepatic metabolism, with inactive metabolites excreted renally (approximately 3-10% unchanged) and fecally (minor). Biliary excretion is negligible.
Primarily renal elimination as unchanged drug; ~75% excreted in urine and ~20% in feces via biliary secretion.
Category C
Category C
Botulinum Toxin Type A
Botulinum Toxin Type A